NEWS
Thrive Initiative Press Release
MPN NEWS | December 14, 2022
MPN Research Foundation Awards Additional $1.8 Million for Blood Cancer Research into Myeloproliferative Neoplasms Dec. 14, 2022 (Chicago) − MPN Research Foundation (MPNRF) announces its 2022 Thrive Initiative recipients for projects that fill research funding gaps, some of which surfaced due to the pandemic. This $1.8 million in awards is in addition to currently funded… Read More »Thrive Initiative Press Release
Blood Brothers
MPN NEWS | December 9, 2022
Growing up in Czechoslovakia four years apart, Josef and Jaroslav Prchal didn’t always agree on things. And that’s still true today. Yet, independently and together, these two physicians/scientists have made practice-changing marks on the global red blood cell landscape — and particularly on polycythemia vera (PV) − both in the research laboratory and medical clinic.… Read More »Blood Brothers
Richard T. Silver, MD
MPN NEWS | September 7, 2022
Before he helped define criteria for the diagnosis of polycythemia vera (PV) and introduced interferon to treat it; before he chaired the guidelines committee for the treatment of chronic myeloid leukemia (CML) for the American Society of Hematology; and long before his name branded an internationally recognized clinic that specializes in myeloproliferative neoplasms (MPNs); Richard… Read More »Richard T. Silver, MD
30 FACTS about MPNs
MPN NEWS | August 22, 2022
Our investments in global, cutting edge, multi-center MPN research have directly advanced knowledge about the causes of these rare, chronic blood cancers, leading to the development of more and better treatments and improved quality of life for people living with an MPN. Clinical trials are an integral part of this process. 30 FACTS ABOUT MPN… Read More »30 FACTS about MPNs
Advances of Note From EHA2022
MPN NEWS | July 29, 2022
The European Hematology Association’s EHA2022 Congress in Vienna brought together global research leaders, practitioners, and other participants in June to share the latest advances in hematology. Among those on MPNs were the following: “ASXL1 mutations accelerate bone marrow fibrosis via EGR1-TNFa axis mediated inflammation and fibrocyte generation in myeloproliferative neoplasms” This study illustrated the crucial role… Read More »Advances of Note From EHA2022
MPN Stem Cells Suffer From ‘Corrupting Influence’
MPN NEWS | July 29, 2022
Interferon has been shown to be very effective in some patients with MPNs, often alleviating their fatigue, enlarged spleen, and other symptoms. Some patients show important additional benefits, such as molecular response, even long-term remission and the delay of disease progression. For others with ET, PV or MF, interferon has no measurable effect. As part… Read More »MPN Stem Cells Suffer From ‘Corrupting Influence’
Sole2Soul for MPN: Hiking for Awareness and a Cure
MPN NEWS | July 26, 2022
This summer, MPN Research Foundation teamed up with Sole2Soul for MPN – an innovative collaboration of the CURE Media Group, the MPN Research Foundation, and the Canadian MPN Research Foundation – to empower those who are closely impacted by MPN blood cancers. This program was created to challenge adventurers while raising funds to fuel change for those… Read More »Sole2Soul for MPN: Hiking for Awareness and a Cure
MPN News from 2022 EHA Congress
MPN NEWS | June 27, 2022
A number of important findings regarding MPNs were featured in June, at the European Hematology Association’s (EHA2022) Congress in Vienna. Some key highlights follow. How to select patients with myelofibrosis for transplantation and how to manage MF patients during a transplant procedure. Related abstract: Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation? Jean Jacques… Read More »MPN News from 2022 EHA Congress
MPN News from 2022 ASCO
MPN NEWS | June 27, 2022
A number of important findings regarding MPNs were featured in June, at the 2022 American Society of Clinical Oncology (2022ASCO) Annual Meeting in Chicago. Some key highlights follow. Rusfertide Shown to Reduce Phlebotomy “The target in treating patients with PV (polycythemia vera) is to chronically maintain adequate hematocrit levels below 45 percent, which reduces the… Read More »MPN News from 2022 ASCO
Identifying and Validating Actionable Biomarkers in MPN
MPN NEWS | May 25, 2022
Research Spotlight on Rebekka Schneider, MD, Director, Department of Cell and Tumor Biology, Aachen University, Germany, and Erasmus MC Cancer Institute, The Netherlands. In MPNs, your blood forming stem cell acquires a mutation, and this leads to more proliferation. In the beginning, you have too many blood cells. Then, in the course of the disease,… Read More »Identifying and Validating Actionable Biomarkers in MPN